FDA Approved: ELAHERE — Supplemental Application (ImmunoGen, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for ELAHERE (mirvetuximab soravtansine) from ImmunoGen, Inc., updating the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Fallopian Tube Cancer
• Peritoneal Cancer

Drugs mentioned

• Elahere (mirvetuximab soravtansine)

Snippet

SUPPL AP for ELAHERE (MIRVETUXIMAB SORAVTANSINE)